Archives: Speakers

Since joining the company in 2017, Husain has played an integral role in countless upgrades and new initiatives designed to improve Skybound’s overall value proposition. Following an appointment to the Group Operations Director in 2022, he has led all aspects of digital transformation at Skybound, winning them 9 awards and counting in this narrow window. Following the application of process design, implementation of new client facing technology and integration of advice tools across the industry – he has just launched the the offshore IFA industry’s first piece of advice technology developed from scratch, offering whole of market comparisons, intuitive recommendations, simplistic plan tracking and backed by the highest compliance standards

Senior Audit Leader with multi-disciplinary experience of over 22 years in the area of digital transformation, technology and business auditing. Expertise in risk and controls within financial services (retail, markets, insurance, investments, wealth), digital, technology, cyber, resilience, emerging technologies, data and sourcing.  Building collaboration and engagement across senior leaders, regulators and control functions.

Currently, Head of Audit with Lloyds Banking Group covering Insurance, Investments, Wealth, Stockbroking business areas and strategic technology platforms, digital transformation, data management and migration. Previously, worked with Deutsche Bank, Bank of Africa UK, Credit Suisse, KPMG and Oracle.

Jim Palma is the Executive Director of TargetCancer Foundation. Since joining TargetCancer Foundation in 2010, Jim has overseen its growth from a small start-up to a nationally recognized foundation supporting comprehensive rare cancer research programs and patient support services. Prior to joining TargetCancer Foundation, he spent eleven years at Fidelity Investments in Boston, MA. Jim is a member of the Board of Directors of the National Organization for Rare Disorders (NORD), and is a founding Co-Chair of the NORD Rare Cancers Coalition. In addition, Jim is a Steering Committee member at the GI Cancers Alliance and the Global Cholangiocarcinoma Alliance. Jim completed studies at the Institute for Nonprofit Management and Leadership at the Questrom School of Business at Boston University, and received his B.A. from Loyola University Maryland.

Giovanni was born in Naples, Italy. While studying Medicine, he volunteered on projects for the poor, sick and lepers in Italy, Albania, India. He was a subinvestigator on 4 oncology clinical trials during his Clinical Oncology in Milan since 2001; moved to Philadelphia, PA, USA in 2005 where enrolled in a PhD program in Genetic Oncology, performing in vitro and in vivo gene therapy studies in cancer models. In 2007 he moved to Boston to lead cancer drug development programs in small biotech companies; at ArQule he led lab research, clinical development and medical affairs and brought 7 molecules to Ph1-3 clinical development. In 2017 he joined Sanofi, where as VP and Head of Oncology Early Development he oversaw development of over 20 clinical experimental drugs, as many preclinical, through teams of ~300 people, besides helping with Business Development and Investor Relations. In addition, Giovanni consulted for a couple of dozen companies and VC funds, scientific societies, and Governments. In 2008 Giovanni founded the nonprofit Professionisti Italiani a Boston, which has hosted 100+ cultural and networking events; in 2014 he founded Scuola PIB, a nonprofit Italian Saturday school with over 170 pupils in 2025